Union Health Ministry Notifies 2026 Amendments to NDCT Rules, 2019 for Pharma Ease

The Union Ministry of Health and Family Welfare notifies the 2026 amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019. The amendments provide for simplified regulatory processes and reduced approval timelines for clinical research and pharmaceutical development, implemented through CDSCO and online portals.

2026 Amendments to NDCT Rules, 2019 (Pharma Ease):

Dimension	Key Details
Nodal ministry	Union Ministry of Health and Family Welfare.
Objective	Provides for tackling regulatory burden, accelerating drug development and clinical research, and promoting ease of doing business while ensuring public health and safety.
Implementing authority	Central Drugs Standard Control Organization (CDSCO) comprises regulation of test licences, clinical trials, and Bioavailability/Bioequivalence (BA/BE) studies.
Digital systems	National Single Window System (NSWS) and SUGAM Portal enable online submission and monitoring through dedicated modules.
Prior-intimation mechanism	Licensing requirement for non-commercial manufacture is replaced with online prior-intimation to CDSCO.
Prior-intimation mechanism	High-risk drugs (cytotoxic, narcotic, psychotropic) remain under test licence requirement.
Timeline reduction	Drug development timelines are reduced by at least 90 days; statutory processing of test licences is cut from 90 days to 45 days.
BA/BE studies	Prior permission is waived for specified low-risk BA/BE studies; an online intimation mechanism is introduced.
Application volumes (BA/BE)	CDSCO processes about 4,000–4,500 BA/BE applications annually.
Application volumes (test licences)	CDSCO handles about 30,000–35,000 test licence applications yearly.
Regulatory efficiency	Enables optimal utilisation of CDSCO manpower and faster oversight by reducing regulatory burden.